Lenvima 10 MG daily dose 30S
Ended Awarded
- Contract number
- SPE2DB25FTA06
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,354
Award facts
- Contract value 100% obligated
- $11,353.77 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $11,353.77 by the Defense Logistics Agency on September 23, 2025, for the supply of Lenvima 10 mg daily dose tablets in quantities of 30. The delivery order, which carries no set-aside designation, is expected to be completed by October 15, 2025, with performance taking place at the contractor's Park Ridge facility. This award is issued under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, a $499,999,999 vehicle valid through November 2026 that authorizes the issuance of firm fixed-price delivery orders for pharmaceutical products supporting Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, demonstrating consistent success in securing DLA contracts for a broad portfolio of prescription medications, biologics, and medical consumables. The company's contract history reflects its capability to deliver specialized pharmaceutical products, including oncology treatments and other branded medications, directly to military health facilities. Lenvima, a targeted cancer therapy, aligns with the company's established business of providing advanced pharmaceutical treatments to support the medical supply needs of Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DB25FTA06?
SPE2DB25FTA06 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 23, 2025.
How much is contract SPE2DB25FTA06 worth?
The government has obligated $11,354 on SPE2DB25FTA06.
Is contract SPE2DB25FTA06 an order under another contract?
Yes. SPE2DB25FTA06 is a delivery order under SPE2DB22D9367, an indefinite delivery contract.
Was contract SPE2DB25FTA06 competed?
The extent of competition for SPE2DB25FTA06 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award